Greenwich LifeSciences Inc. Common Stock
(NASDAQ:GLSI)
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing (HER2/neu) cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is headquartered in Stafford, Texas.
GLSI Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$9.8900 |
Previous Close Volume |
13210 |
Latest News
- Greenwich LifeSciences Partners with GIM in Italy 26 Nov 2024 06:24:38
- Greenwich LifeSciences Provides Update on Corporate Events 18 Nov 2024 06:24:23
- Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain 01 Aug 2024 06:09:47
- Greenwich LifeSciences Set to Join Russell 2000 Index Again 26 Jun 2024 07:39:58
- Greenwich LifeSciences Announces $2.5 Million Private Placement 14 Jun 2024 06:10:00
- Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025 13 Mar 2024 06:10:25
- Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe 12 Mar 2024 06:10:18
- Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries 27 Feb 2024 06:10:28
- Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators 22 Feb 2024 06:10:25
- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01 14 Feb 2024 06:10:22